1624. Hepatitis C Elimination and Treatment of HCV Infection in IDU
Session: Symposium: The ID Specialist and the Opioid Epidemic: What You Need to Know Now
Friday, October 5, 2018: 2:00 PM
Room: W 2005-2024
Judith I. Tsui, MD MPH, Medicine, University of Washington, Seattle, WA

Dr. Judith Tsui is an Associate Professor of Medicine at the University of Washington, based at Harborview Medical Center in Seattle, who is an internist board certified in Addiction Medicine. She is a clinician investigator who is committed to research that improves the lives of patients with substance use disorders. Dr. Tsui is currently involved in a number of clinical trials that intervene on patients with opioid use disorders and injection drug use since completing a NIH/NIDA-funded career development award (K23DA027367; “HCV and Pain in Substance Users with and without HIV”). She is currently the site-PI in Seattle for an 8-site PCORI-funded randomized controlled trial comparing models of care to support HCV treatment among persons who inject drugs. She was awarded a grant from NIH/NIDA to perform a pilot randomized trial of a mobile phone application for video-based directly observed therapy for buprenorphine treatment and is also a site co-investigator of two NIDA clinical trials network studies related to treatment for opioid use disorders (CTN-0069 and CTN-0074). She received her undergraduate degree from Princeton University and medical degree from New York University. She completed residency training at Oregon Health Sciences University, followed by obtaining a master of public health in epidemiology at Emory University, and a research fellowship at University of California San Francisco. Prior to joining the University of Washington, she was a faculty member of Boston University’s School of Medicine and active in treating opioid use disorders and hepatitis C in primary care at Boston Medical Center. Upon joining University of Washington, she contributed to a successful grant to Substance Abuse and Mental Health Services Administration (SAMHSA) to fund an office-based buprenorphine program at the Adult Medicine Clinic at Harborview Medical Center. In Seattle she provides care for hepatitis C among persons who inject drugs Evergreen Treatment Services, a local methadone clinic, and Harborview Medical Center.


Disclosures:

J. I. Tsui, Gilead: Grant Investigator , Research support .

Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.